Thursday, July 01, 2010
Stem cell scientists launch effort to prevent fraudulent treatment - Office of Communications & Public Affairs - Stanford University School of Medicine
"... The use of quotes from well-regarded stem cell scientists and physicians is not uncommon on unscrupulous Internet websites, according to Weissman. Frequently these experts are unaware that their names are being used, and the quotes are fabricated or taken out-of-context from some other source.
As a result of the task force’s efforts to publicize these and other abuses, the ISSCR recently launched a publicly available website (www.closerlookatstemcells.org) where patients can learn more about stem cell biology, learn what questions to ask of potential clinics, and even submit a specific website for further investigation by the ISSCR."
Miradx - "PreOvar" test (KRAS mutation
KRAS Variant Grand Round Presentation ("coming soon")
Mon, 03/08/2010 - 13:19 — admin
To learn more about PreOvar, review the On-line Grand Rounds presented by Joanne Weidhaas, M.D., Ph.D., an Assistant Professor at Yale University
in the Department of Therapeutic Radiology.
Management of rare ovarian cancers: The experience of the French website «Observatory for rare malignant tumours of the ovaries» by the GINECO group
Background
Non-epithelial ovarian cancers are rare; their natural history is poorly understood and prognostic factors remain unclear. A French website (www.ovaire-rare.org) was developed to collect clinical cases and tumour samples in order to better define prognostic factors and develop specific trials. We report the results of the first 100 patients with germ cell (GCT) and sex cord-stromal (SCT) tumours.Conclusions
This online observatory allows assessing medical practice for GCT and SCT in France. Histological discrepancies between diagnosis and second opinion confirm the need for systematic review before treatment. Extension to other rare gynaecologic malignancies is on-going.Clinical Management of Borderline Tumours of the Ovary – Experience from the “Berlin Online Tumour Conference for Gynaecological Malignancies” — Anticancer Research
Abstract
Borderline ovarian tumour (BOT) represents a rare and special tumour entity. Despite a generally favourable prognosis for patients with BOT, the presence of invasive peritoneal implants decreases the survival rate to 30-50%. In contrast to ovarian cancer, only few data exist concerning the current clinical management of patients with BOT. For this reason, the present analyses were performed for patients with BOT who were admitted into our online tumor conference for patients with gynaecological malignancies. Based on the results discussed in this article, the current aspects and problems regarding the diagnostic, surgical and conservative treatment and aftercare management of patients with BOT are considered.
Arrayit Corporation Receives Registered Trademark for OvaDx(R) - financial news
"Arrayit's OvaDx(R), the market's first comprehensive diagnostic screening test for ovarian cancer, uses approximately 100 proteomic biomarkers to identify molecular beacons of ovarian cancer that accumulate in the bloodstream as soon as an ovarian tumor begins to develop. OvaDx(R) detects both early and late stage ovarian cancer with high sensitivity and specificity using Arrayit's proprietary microarrays, which are tiny medical devices that screen large numbers of patient samples in a highly miniaturized and automated manner. OvaDx(R) leverages Arrayit's patented manufacturing technology and will be marketed and sold upon FDA approval by the company's subsidiary Arrayit Diagnostics, Inc."
Subscribe to:
Posts
(
Atom
)
Posts
